Home » Newsletters » BioWorld Science

BioWorld Science

July 22, 1998

View Archived Issues

Antipsoriatic dihydrofolate reductase inhibitors available for licensing from BTG

Long-term use of salmeterol for exercise-induced asthma results in decreased duration of action

Hokuriku designs potent, orally active, metabolically stable TxA2/CysLT1 antagonists

Erythromycins from Taisho for Gram-positive infections

Morinaga Milk develops peptides with antifungal activity

Benzodiazepine omega3 receptor ligands with anxiolytic, anticonvulsant and antiarthritic effects

Mer-WF-1726: new antitumor substance isolated from natural source

Spotlight on sigma-receptors as a target for intervention in CNS disorders

Cell Therapeutics licenses rights to PG-TXL

Icos begins phase II multiple-dose trial in multiple sclerosis patients

Kos files European marketing application for Niaspan and begins clinical trials with Nicostatin

Analgesic effects of dosulepin in patients with cancer-related pain

GV-150013 has dual therapeutic potential in treating alcoholism and sleep disorders

Vigabatrin is effective for treating alcohol withdrawal syndrome

Preclinical results point to anxiolytic efficacy for Yoshitomi benzodiazepine

SomatoKine progresses to phase II for a new disease indication

Lisofylline development timetable readjusted, marketing agreements revised

Scientists report success in achieving tolerance in transplantation models

L-054264, the first small-molecule sst2 receptor agonist reported

Inhibitors of iNOS described by Ono scientists

FDA clears SSRI for depression

Oncologic Drugs Advisory Committee meets for three days in September

Patient dosing begins in phase Ib trial of stroke drug from NPS

Roche to sell participation in DePuy

Neurogen's epilepsy compound advances through clinical trials

Sepracor and Janssen sign licensing agreement for cisapride metabolite

French and Israeli researchers synthesize peptides active against slow-growing, anaerobic bacteria

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...